Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor, Vanzacaftor-Tezacaftor-Deutivacaftor
Drugobservational
NCT Number: NCT04732910
This observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal current measurement (ICM), nasal potential difference (NPD) and sweat chloride in a post-approval setting in patients with cystic fibrosis (CF).
Interested in participating?
Request Info6 month and older
All sexes
Observational
Charité - Universitätsmedizin Berlin, Berlin, State of Berlin, Germany
Cystic fibrosis transmembrane regulator (CFTR) biomarker (intestinal current measurement (ICM), nasal potential difference (NPD), sweat chloride) before the start of therapy and 12 and 52 weeks after initiation of therapy Clinical parameters (anthropometry, lung function, lung magnetic resonance imaging (MRI), lung computer tomography (CT)) before the start of therapy and after initiation of therapy Assessment of airway secretion specimens before the start of therapy and after initiation of therapy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
observational
Time frame: 12 weeks
Absolute change from baseline of the chloride secretory ion current induced by cyclic adenosine monophosphate (cAMP) stimulation (forskolin/3-isobutyl-1-methylxanthine (IBMX)) in rectal tissue determined by intestinal current measurement (ICM) as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker
Time frame: quaterly in the first year, yearly thereafter up to 5 years
Absolute change from baseline in percent predicted forced expiratory volume in 1 second (FEV1) in spirometry
Time frame: 12 weeks
Absolute change from baseline total chloride response (zero chloride and isoproterenol) in nasal potential Difference (NPD) as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker
Time frame: 12, 52 weeks, yearly thereafter up to 5 years
Absolute change from baseline of the chloride concentration in Gibson-Cooke pilocarpine iontophoresis sweat test as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker
Time frame: quaterly in the first year, yearly thereafter up to 5 years
Absolute change from baseline of the lung clearance index (LCI)
Time frame: 12, 52 weeks, yearly thereafter up to 5 years
Absolute change from baseline in lung magnetic resonance imaging (MRI) score (Heidelberg MRI score ranging from 0 to 72 with higher values associated with worsening of the outcome; Eichinger et al. Eur J Radiol 2012)
Time frame: 52, 104 weeks
Absolute change from baseline in lung computer tomography (CT) score (Brody score ranging from 0 to 40,5 with higher values associated with worsening of the outcome; Brody et al. J Thorac Imaging 2006)
Time frame: 12, 52 weeks, yearly thereafter up to 5 years
Absolute change from baseline in paranasal sinus magnetic resonance imaging (MRI) score (Sinunasal MRI score ranging from 0 to 68 with higher values associated with worsening of the outcome; Sommerburg et al. Ann Am Thorac Soc 2020)
Time frame: 12, 52 weeks, yearly thereafter up to 5 years
Absolute change from baseline in fecal elastase-1 (FE-1) levels
Time frame: quaterly in the first year, yearly thereafter up to 5 years
Absolute change from baseline in weight
Time frame: 4, 12, 52 weeks, yearly thereafter up to 5 years
Absolute change in shannon index representing the alpha-diversity in sputum samples
Time frame: 4, 12, 52 weeks, yearly thereafter up to 5 years
Absolute change in the elastic modulus (G') in sputum samples measured with a rheometer
Time frame: 4, 12, 52 weeks, yearly thereafter up to 5 years
Absolute change in the viscous modulus (G'') in sputum samples measured with a rheometer
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The Cystic Fibrosis Questionnaire-Revised is a disease-specific health-related quality of life instrument for individuals with cystic fibrosis. Scores are standardized on a 0-100 scale. Minimum: 0; Maximum: 100. Higher scores indicate better health-related quality of life. Absolute change from baseline is calculated as follow-up score minus baseline score.
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The Patient Health Questionnaire-9 is a 9-item self-report measure assessing depressive symptom severity over the past two weeks. Total score range: 0-27. Minimum: 0; Maximum: 27. Higher scores indicate more severe depressive symptoms. Absolute change from baseline is calculated as follow-up score minus baseline score.
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The Generalized Anxiety Disorder-7 is a 7-item self-report measure assessing anxiety symptom severity over the past two weeks. Total score range: 0-21. Minimum: 0; Maximum: 21. Higher scores indicate more severe anxiety symptoms. Absolute change from baseline is calculated as follow-up score minus baseline score.
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The Child Behavior Checklist for Ages 1½-5 is a parent-reported measure assessing emotional and behavioral problems in children aged 18 months to 5 years. The Total Problems raw score ranges from 0-198. Minimum: 0; Maximum: 198. Higher scores indicate more emotional and behavioral problems. Absolute change from baseline is calculated as follow-up score minus baseline score.
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The Child Behavior Checklist for Ages 6-18 is a parent-reported measure of emotional and behavioral problems. Raw total problem scores range from 0-226. Minimum: 0; Maximum: 226. Higher scores indicate more behavioral and emotional problems. Absolute change from baseline is calculated as follow-up score minus baseline score.
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The Youth Self-Report for Ages 11-18 is a self-report measure of emotional and behavioral problems, corresponding to the Child Behavior Checklist. Raw total problem scores range from 0-224. Minimum: 0; Maximum: 224. Higher scores indicate more behavioral and emotional problems. Absolute change from baseline is calculated as follow-up score minus baseline score.
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The Strengths and Difficulties Questionnaire is a behavioral screening questionnaire. The Total Difficulties Score ranges from 0-40. Minimum: 0; Maximum: 40. Higher scores indicate more emotional and behavioral difficulties. Absolute change from baseline is calculated as follow-up score minus baseline score.
Time frame: quarterly in the first year, yearly thereafter up to 5 years
The 22-Item Sino-Nasal Outcome Test assesses symptom severity and health-related quality of life in sinonasal disease. The total score ranges from 0-110. Minimum: 0; Maximum: 110. Higher scores indicate more severe symptoms and poorer quality of life. Absolute change from baseline is calculated as follow-up score minus baseline score.
Contact information is provided by the study sponsor or research team.
Charite University, Berlin, Germany
Other
CFTR Biomarker Studie Bei Patient*Innen Mit Mukoviszidose Und CFTR-Modulatortherapie
Acronym: Modulate-CF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02417740
Cardiovascular Abnormalities, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06654752
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Birmingham, Alabama, United States
View Trial DetailsNCT00001532
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07283770
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Overland Park, Kansas, United States
View Trial Details